Finally, the effects of switching from different basal insulin analogues to either icodec or glargine U100 were investigated in an open-label RCT including 154 participants with type 2 diabetes and a baseline HbA1c of 53–86 mmol/mol (7.0–10.0%) [25]. This evidence concerns the gene INS and type 2 diabetes mellitus.